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ABSTRACT 
 
Introduction: The influence and interactions of various genetic, hormonal, environmental and 
nutritional factors and risks for decreased bone mineral density in older age are not yet clear. 
The aim of this study was to examine relationship between reduced exposure to estrogen over 
a lifetime (early age at menopause, shorter period between menarche and menopause) and bone 
mineral density in older women. 
Methods: A total of 60 women, aged 60-75 years were included and assigned to osteoporosis 
group (n=30), or control group with normal bone mineral density or osteopenia (n=30). The 
values of bone mineral density were obtained by dual energy X-ray absorptiometry (DXA) at 
the lumbar spine (L2-L4) and proximal femur. 
Results: Women with osteoporosis entered the menopause at a younger age (43.03±3.18 years) 
compared to women without osteoporosis (51.93± 2.30 years) and the difference was 
statistically significant, p=0.0001. In addition, women with osteoporosis had shorter timespan 
between menarche and menopause (28.33±3.31 years), compared to women without 
osteoporosis (38.43±2.48 years), which was statistically significant, p=0.0001. 
Conclusion: Reduced exposure to estrogen over a lifetime because of early menopause, and 
shorter timespan between menarche and menopause may be associated with decreased bone 
mineral density and osteoporosis in postmenopausal women. 
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INTRODUCTION  
 
Osteoporosis is a skeletal disorder characterized by compromised bone strength, which depends 
on bone density. Bone quality refers to bone architecture, metabolic turnover, damage 
accumulation and demineralization and if low may present increased risk of fracture (1). In 
2010, 22 million women and 5.5 million men from the 27 countries of the European Union 
(EU27) were estimated to have osteoporosis, with the incidence of 3.5 million fragility fractures 
of which 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 
1,800,000 other fractures (pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other 
femoral fractures) (2). Older patients are much more susceptible to fracture at any given bone 
mineral density than are younger patients because of various factors, including the quality of 
aging bone, which involves more factors than bone mineral density (3). Osteoporosis-related 
fractures can increase pain, disability, nursing home placement, total health care costs and 
mortality (4). Causally related deaths comprised 17-32% of all deaths associated with hip 
fracture (depending on age) and accounted for more than 1.5% of all deaths in the population 
aged 50 years or more (5). Consequences of vertebral fracture, even asymptomatic ones, include 
loss of height, back pain, kyphosis, protuberant abdomen, and decreased lung vital capacity, 
loss of self-esteem, sleep disorders, depression, further fractures and increased mortality (6). 
The results of the study of Ong T, et al. showed that inpatient and 1-year mortality after vertebral 
fragility fracture was between 0.9 and 3.5%, and 20 and 27%, respectively, between 34 and 
50% were discharged from hospital to a care facility. Older age and increasing comorbidities 
was associated with longer hospital stay and higher mortality (7).  
Osteoporosis has a complex etiology and is considered a multifactorial polygenic disease in 
which genetic determinants are modulated by hormonal, environmental, and nutritional factors 
(8). The female reproductive system plays a major role in regulating the acquisition and loss of 
bone by the skeleton from menarche through senescence (9). Menopause and the accompanying 
loss of ovarian estrogens are associated with declines in bone mineral density (10). Estrogen 
deficiency increases the high turnover, increases the lifespan of osteoclasts and promotes 
osteoblastic apoptosis (11). At menopause, decreased gonadal sex steroid production normally 
leads to rapid bone loss - the most rapid bone loss associated with decreased estrogen levels 
occurs in the first 8-10 years after menopause, with slower age-related bone loss occurring 
during later life (9). Age-related bone loss, in both men and women, results when bone 
remodeling becomes uncoupled and bone resorption exceeds bone formation - the roles and 
interactions of various hormonal, genetic, and other factors in bone loss and risk for decreased 
bone health are not yet clear (12). The incidence of osteoporotic fracture starts to increase in 
older age. Further understanding of the relative contributions of the female reproductive system 
and each of the other factors to development and maintenance of the female skeleton, bone loss, 
and fracture risk will lead to improved approaches for prevention and treatment of osteoporosis 
(9). 
The aim of this study was to examine association between reduced exposure to estrogen over a 
lifetime, reflected as early menopause and shorter timespan between menarche and menopause, 
and bone mineral density in postmenopausal women. 
 
METHODS 
 
Study design 
 
A total of 60 women, aged 60-75 years were included in this study. The women who met 
following criteria were included into study: women aged 60 to 75 years, women who do not 
use hormone replacement therapy, women whose findings of bone densitometry was at the level 
of osteoporosis, women whose findings of bone densitometry was at the level of osteopenia or 
normal. The exclusion criteria were: women younger than 60 and older than 75 years, women 
who use hormone replacement therapy, women who have a disease that can cause osteoporosis, 
women who use drugs that may cause osteoporosis. 
Two groups of women were formed based on bone mineral density values. In the study group 
(n=30) were included women whose bone mineral density was at the level of osteoporosis, and 
in the control group (n=30)  were women with bone mineral density at the normal level or at 
the level of osteopenia.  
The values of bone mineral density were obtained by measuring bone mineral density using 
dual energy X-ray absorptiometry (DXA) at the lumbar spine (L2-L4) and proximal femur. 
Statistical analysis 
Results of the analysis are presented in the tables and graphs. To compare differences between 
groups chi-square test and Student's t test were used. Results of these tests were considered 
statistically significant at a confidence level of 95% or in p<0.05. Statistical analysis was done 
by using the statistical package MedCalc v12.7 (Antwerp, Belgia). 
 
 
RESULTS 
 
The average age of women in the study group was 68.1 years, and in the control group was 68.7 
years (Figure 1). There was no statistically significant differences between these two groups, 
t=0.031; p=0.975 (Table 1). 
The average age of menopause in the study group was 43.0333 years and and in the control 
group was 51.9333 years (Figure 2). There was statistically significant differences between 
these two groups, t=-12.419; p=0.0001 (Table 2). 
There was statistically significant differences in age of menopause expressed in decades of life 
between the study group and the control group, χ2=33.818; p=0.0001 (Table 3). 
 
The average period between menarche and menopause in the study group was 28.3333 years 
and and in the control group was 38.4333 years (Figure 3). There was statistically significant 
differences between these two groups, t=7.198; p=0.0001 (Table 4). 
There was statistically significant differences in period between menarche and menopause 
expressed in range of years between the study group and the control group, χ2=36.533; 
p=0.0001 (Table 5). 
 
DISCUSSION  
 
Estrogen is the key regulator of bone metabolism in both men and women (10). Estrogen 
exposures occur throughout life, including prenatally, and change with reproductive events, 
such as menarche and menopause (13).  
In this study was examined whether reduced exposure to estrogen over a lifetime (early age at 
menopause, shorter period between menarche and menopause) leads to low bone mineral 
density in the old age.  
The studies have discrepant results about the relation between estrogen related events and 
osteoporosis. 
The aim of prospective population-based observational study of Svejme O, et al. was to evaluate 
of the long-term effects of early menopause on mortality, risk of fragility fracture and 
osteoporosis. Menopause before age 47 was associated with increased mortality risk and 
increased risk of sustaining fragility fractures and of osteoporosis at age 77. Women with early 
menopause had a risk ratio of 1.83 (95% CI 1.22-2.74) for osteoporosis at age 77, a risk ratio 
of 1.68 (95% CI 1.05-2.57) for fragility fracture and a mortality risk of 1.59 (95% CI 1.04-2.36) 
(14). The result of Sullivan SD, et al. study showed that whole-body bone mineral density was 
lower in women who reported menopause before age 40 years than in women who reported 
menopause at ages 40 to 49 years and women who reported menopause at age 50 years or older. 
Left hip bone mineral density was lower in women who underwent menopause before age 40 
years than in women who underwent menopause at age 50 years or older and total spine bone 
mineral density was lower in women who underwent menopause before age 40 years than in 
women who underwent menopause at age 50 years or older and women who underwent 
menopause at ages 40 to 49 years (15). In the study of Cavkaytar S, et al. fertility duration over 
33 years (years of menstruation) had a statistically significant protective effect against 
osteoporosis in women with spontaneous menopause (16). The result of the study of Parker SE, 
et al. support the hypothesis that lifetime cumulative exposure to estrogens is protective against 
osteoporosis (13). Sioka C, et al. found that in postmenopausal women the cumulative exposure 
to endogenous estrogens, measured as years of menstruation, seems to be a significant 
protective factor against the development of postmenopausal osteoporosis. Age at menopause 
between 40 and 45 years correlated with low bone mineral density (17). The result of the study 
of Comim FV, et al. suggest that premenopausal hirsutism and/or oligomenorrhea may be 
associated with an increased risk of fracture postmenopause, particularly in the humerus and 
lower leg (18). The study of Mohammadi F, et al. examined the relationship between 
reproductive characteristics and bone mineral density in postmenopausal women aged 45-
71 years. Age at menopause was not significantly correlated with bone mineral density (19). In 
the study of Gerdhem P. and Obrant KJ. was found that age at menarche or menopause seems 
to be of limited or no importance as a risk factor for osteoporosis when subjects are age 75 or 
older (20). 
The aim of this study was to examine relationship between reduced exposure to estrogen over 
a lifetime (early age at menopause, shorter period between menarche and menopause) and bone 
mineral density in older women. There was a statistically significant difference related to age 
of menopause between the women with osteoporosis and women without osteoporosis. Also, 
there was regestered statistically significant difference related to the period between menarche 
and menopause, between the women with osteoporosis and women without osteoporosis.  
Average age of menopause in the women with osteoporosis was 43.03±3.18 years and in 
women without osteoporosis 51.93±2.30 years. Average period between menarche and 
menopause in the women with osteoporosis was 28.33±3.31 years and in women without 
osteoporosis 38.43±2.48 years. 
The result of this study showed that the deficit of estrogen over a lifetime is associated with a 
decrease in bone mineral density. Kapetanović A. and Advić D. found that healthy lifestyle has 
positive impact on bone tissue and has the potential to preserve bone mass in postmenopausal 
women with estrogen deficiency in their menstrual history (21,22). 
 
CONCLUSION 
 
Reduced exposure to estrogen over a lifetime because of early menopause, and shorter 
timespan between menarche and menopause may be associated with decreased bone mineral 
density and osteoporosis in postmenopausal women. 
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TABLES 
 
Table 1. Comparison of average age by groups 
Age 
 N  SD SE Minimum Maximum 
Study  30 68.10 4.581 .836 60 75 
Control     30 68.07 3.581 .654 63 75 
Total  60 68.08 4.077 .526 60 75 
t=0.031; p=0.975 
SD: Standard deviation; SE: Standard error  
 
 
Table 2. Comparison of average age of menopause by groups 
Age of menopause (years) 
 N  SD SE Minimum Maximum 
Study  30 43.0333 3.17841 .58030 35.00 50.00 
Control  30 51.9333 2.30342 .42055 48.00 56.00 
Total  60 47.4833 5.26418 .67960 35.00 56.00 
t=-12.419; p=0.0001 
SD: Standard deviation; SE: Standard error  
 
Table 3. Comparison of age of menopause expressed in decades of life by groups 
 Age of menopause (decades of life) 
 Group      Total  
   Study    Control  
 
    Age of menopause    
30-40 years N 6 0 6 
% 20.0 0.0 10.0 
41-50 years N 24 9 33 
% 80.0 30.0 55.0 
51-60 years N 0 21 21 
% 0.0 70.0 35.0 
   Total N 30 30 60 
% 100.0 100.0 100.0 
χ2=33.818; p=0.0001 
 
 
 
 
 Table 4. Comparison of average period between menarche and menopause by groups 
Average period between menarche and menopause (years) 
 N  SD SE Minimum Maximum 
Study              30 28.3333 3.31489 .60521 21.00 37.00 
Control      30 38.4333 2.48698 .45406 35.00 43.00 
Total     60 33.3833 5.86310 .75692 21.00 43.00 
t=7.198; p=0.0001 
SD: Standard deviation; SE: Standard error  
 
Table 5. Comparison of period between menarche and menopause expressed in range of years 
by groups 
 
Period between menarche and menopause (range of years) 
 Group    Total   
Study      Control      
 
Period between menarche and 
menopause 
(range of years) 
20-25 
years 
N       6 0 6 
% 20.0 0.0 10.0 
26-30 
years 
N 16 0 16 
% 53.3 0.0 26.7 
31-40 
years 
N 8 22 30 
% 26.7 73.3 50.0 
40-45 
years 
N 0 8 8 
% 0.0 26.7 13.3 
Total N 30 30 60 
% 100.0 100.0 100.0 
χ2=36.533; p=0.0001 
 
  
FIGURES 
 
Figure 1. The average age of women in the study and in the control group 
 
 
 
 
Figure 2. The average age of menopause 
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